Mission and advantages   Extensive experience   Benefits and clients   Downloads   Consulting and services   Mecical services   Qualification   Achievements   Overview   Season's Greetings 2015   BPI Position Paper 2015   Season's Greetings 2014   Season's Greetings 2013   Season's Greetings 2012   Season's Greetings 2011   Season's Greetings 2010   Season's Greetings 2009   Season's Greetings 2008   Season's Greetings 2007   Overview   Phone / E-Mail / Fax   Imprint   Overview   Partner & Societies   Friends Quickfinder About us Achievements Advantages Benefits Consulting Contact Downloads E-Mail Experience Fax Imprint Medical Service Mission Nobel Prize Winners Phone Public Affairs Qualification Service Scientific and strategic consulting DR. RIETHMÜLLER M/R/S is able to provide all of the services listed below. Please feel free to contact us should you require any additional information. Preclinic and clinic The company prepares and evaluates detailed development plans, including pharmaceutical development, pharmacology, toxicology, pharmacokinetics and clinical Phases I to IV. We respect ICH-GMP, GLP, GCP and regional guidelines (FDA, CHMP). Cost calculations of developments are performed. Services and scientific areas We set up files for Marketing authorization approval Orphan drug designation Product pricing. In Europe we prepare submissions/notifications to conduct clinical studies Investigational Medicinal Product Dossier (IMPD) EudraCT Number Ethic Committee. For the successful performance of clinical studies we cooperate with highly qualified Clinical investigators and experts CROs: monitoring of studies, statistics Health authorities. Indications Clinical and preclinical activities have been carried out by us in numerous benign and oncologic indications, e.g. CNS, cardiovascular, respiratory, metabolic, endocrine, infectious, immunologic, gastro-intestinal, gynecologic and urologic diseases, and in the treatment of pain. Compounds Longstanding experience has been gained by the team with new small chemical entities, recombinant drugs, antibodies, generics, and phytopharmaceuticals.